PharmaShots | Incisive News in 3 Shots

Subscribe Now

Primary Progressive

Roche's Ocrevus (ocrelizumab) Shorter 2-Hour Infusion Time Receives EMA's Approval for Relapsing or Primary Progressive Multiple Sclerosis

Roche's Ocrevus (ocrelizumab) Shorter 2-Hour Infusion Time Receives EMA's Approval for Relapsing or Primary Progressive Multiple S...

May 28, 2020

Contact Us

First Floor, B-66, Sector 63 Noida, Uttar Pradesh, INDIA - 201301
+91-120 428 0707
connect@pharmashots.com
Newsletter

Our Information

Follow Us